Cancer API Market is predicted to reach USD 76.3 billion at a CAGR of 5.88% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Cancer API Market”.

The Cancer API market is projected to register a CAGR of 5.88% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global Cancer API market— Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceuticals Industries Ltd (India), Biocon (India), and Beta Drugs Limited (India). Other key players contributing to the market growth include Axplora (Germany), Bulat Pharmaceutical (India), Avra Laboratories Pvt Ltd (India), Biochem Pvt. Ltd (India), and Mac-Chem Products (India) Pvt. Ltd (India), and others.

Market Highlights

The global Cancer API market is accounted to register a CAGR of 5.88% during the forecast period and is estimated to reach USD 76.3 billion by 2032.

The growth of the global Cancer API market is attributed to the increasing prevalence of cancer is a significant driver for the global cancer API market. Cancer remains a major global health concern, with a rising incidence observed across different regions and populations. For instance, according to the World Health Organization (WHO), cancer is one of the leading causes of morbidity and mortality worldwide, accounting for an estimated 10 million deaths in 2020. However, the Stringent regulatory requirements are anticipated to hamper the market growth.

Access full report @ https://www.marketresearchfuture.com/reports/cancer-api-market-6243

Segment Analysis

The global Cancer API market has been segmented based on drug type, manufacturer type, type of synthesis, indication, and region.

On the basis of drug type, the global cancer API market has been segmented into into innovative oncology APIs and generic oncology APIs.

On the basis of manufacturer type, the global cancer API market has been segmented into captive manufacturers and merchant manufacturers.

On the basis of type of synthesis, the global cancer API market has been segmented into synthetic oncology APIs and biotech oncology APIs.

The cancer API market, based on end user, has been segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, liver cancer, cervical cancer, others including pancreatic cancer, thyroid cancer, and bladder cancer..

Regional Analysis

The global Cancer API market, based on region, has been divided into North America, Europe, Asia-Pacific, and Middle East & Africa. The North America further includes US and Canada. The Europe includes countries namely Germany, France, UK, Italy, Spain, and Rest of Europe. The Cancer API market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and Rest of Asia-Pacific. Moreover, the Rest of the World comprises of Middle East, Africa, and Latin America.

North America is predicted to account for the highest proportion of the global cancer API market, among all regions. Factors such as the rising prevalence of cancer, a growing preference for personalized medicine, an increase in private and public sector funding, and rapid advancements in cancer technologies are driving the market for cancer APIs in the North America region. Furthermore, according to United States Cancer Statistics, in the US in 2019, there were 1,752,735 new cancer cases recorded and 599,589 cancer deaths. There were 439 new cancer cases recorded for every 100,000 people, and 146 individuals died from cancer. Moreover, the growing adoption of biosimilar routes in the US is boosting the cancer API market in the US. For instance, according to an IQVIA (US) report issued in 2020, the US spends more on biologics than other developed nations, which is responsible for the price reduction of cancer drugs generated through biotech cancer APIs, including cancer therapy

The Europe cancer API market is predicted to increase significantly throughout the projection period. The market is likely to be driven by increased research funding and the local presence of major industry players in this area. The number of pharmaceutical firms in Europe is expanding as investments increase. Furthermore, countries such as the UK, Germany, France, and Italy have well-established healthcare systems and extensive research activities. Moreover, the region's commitment to preventive healthcare, as well as the increased emphasis on personalized medicine are driving demand for cancer APIs in Europe. Additionally, leading pharmaceutical businesses, academic institutions, and research organizations are in the region, supporting innovation and propelling the industry ahead.

The existence of economies such as China and India, on which the world relies for low-cost API production, is advantageous to the region. Rising healthcare spending in the region is expected to drive market expansion. The rising burden of cancer cases, greater knowledge of the diseases and treatment of the early-onset cancer epidemic, and increased new products being launched are all factors contributing to market expansion. Furthermore, according to the GLOBOCAN 2020 factsheet, 1,324,413 new cancer cases were reported in India in 2020 (678,383 females and 646,030 males). Furthermore, according to the ICMR 2021 Report, the number of cancer patients in India is predicted to climb from 26.7 million in 2021 to 29.8 million in 2025. Therefore, the increasing prevalence of cancer will further help the cancer API market in the Asia-Pacific region to propel.

The growing government support, rising public-private partnerships, and increased funding are all contributing to the growth of the rest of the world cancer API market. In addition, the governments in the region provide tax breaks, cheaper land, incubators, and direct investment, which has encouraged local pharmaceutical firms to expand their capabilities and capacities in order to contribute to improved healthcare services. The UAE, Saudi Arabia, Oman, and Muscat are the most appealing places for the pharmaceutical business. This is projected to boost demand for cancer APIs and speed up market expansion in the future years. In addition, the government and regulatory bodies are providing favorable support to researchers and market companies in order to develop cancer APIs for treatment of the region's population. These variables are expected to have a gradual impact on the rest of the world cancer API market.

Key Findings of the Study

• The global Cancer API market is expected to reach USD 76.3 billion by 2032 at a CAGR of 5.88% during the forecast period.


• The Europe region held the second largest market share of the global market, due to by increased research funding and the local presence of major industry players in this area.


• Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceuticals Industries Ltd (India), Biocon (India), and Beta Drugs Limited (India). Other key players contributing to the market growth include Axplora (Germany), Bulat Pharmaceutical (India), Avra Laboratories Pvt Ltd (India), Biochem Pvt. Ltd (India), and Mac-Chem Products (India) Pvt. Ltd (India), and others. and others are the key players in the market.